Sarepta Therapeutics (NASDAQ:SRPT) Stock Keeps “Sell” Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday, MarketBeat.com reports. They presently have a $5.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential downside of 71.11% from the company’s previous close.

Other analysts have also recently issued reports about the company. Benchmark restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday, September 9th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, July 9th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. JPMorgan Chase & Co. dropped their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. Finally, William Blair raised shares of Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and seven have issued a Sell rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average price target of $22.71.

Sarepta Therapeutics Stock Down 1.0%

Shares of Sarepta Therapeutics stock traded down $0.18 on Monday, reaching $17.31. 2,690,375 shares of the company were exchanged, compared to its average volume of 3,060,234. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.97, a PEG ratio of 0.27 and a beta of 0.38. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a one year low of $14.68 and a one year high of $25.32. The company has a 50-day moving average of $19.02 and a 200 day moving average of $18.82.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm’s revenue for the quarter was down 34.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.02 earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics will post 3.27 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently modified their holdings of the stock. Tidal Investments LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $183,000. Baird Financial Group Inc. increased its holdings in shares of Sarepta Therapeutics by 7.6% during the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 901 shares during the period. Nykredit A S acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $43,000. Corient Private Wealth LP raised its position in shares of Sarepta Therapeutics by 273.4% in the second quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 26,880 shares in the last quarter. Finally, Amundi bought a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $350,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.